Search research articles
Contact Us
Filters
Showing results (31-40 of 52) with videos related to
Page
of 6
Sort By:
BJC Reports
|
November 8, 2024
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Dana M Roque, Eric R Siegel, Natalia Buza, et al.
Journal of Gynecologic Oncology
|
August 25, 2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional study
Burak Zeybek, Emily Webster, Natalia Pogosian, et al.
Annals of Surgical Oncology
|
June 26, 2023
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Julia H Gelissen, Naomi N Adjei, Blair McNamara, et al.
Gynecologic Oncology
|
August 10, 2021
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu
Joan Tymon-Rosario, Eric R Siegel, Stefania Bellone, et al.
Gynecologic Oncology
|
January 27, 2023
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo
Chanhee Han, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology
|
January 7, 2023
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
Dennis Mauricio, Stefania Bellone, Levent Mutlu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sangini S Sheth, Ji Eun Oh, Stefania Bellone, et al.
Gynecologic Oncology
|
May 31, 2022
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu
Ghanshyam Yadav, Dana M Roque, Stefania Bellone, et al.
Clinical & Experimental Metastasis
|
June 22, 2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Levent Mutlu, Blair McNamara, Stefania Bellone, et al.
British Journal of Cancer
|
March 4, 2024
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Dana M Roque, Eric R Siegel, Natalia Buza, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 52) with videos related to
Sort By:
Page
of 6
BJC Reports
|
November 8, 2024
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Dana M Roque, Eric R Siegel, Natalia Buza, et al.
Journal of Gynecologic Oncology
|
August 25, 2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional study
Burak Zeybek, Emily Webster, Natalia Pogosian, et al.
Annals of Surgical Oncology
|
June 26, 2023
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Julia H Gelissen, Naomi N Adjei, Blair McNamara, et al.
Gynecologic Oncology
|
August 10, 2021
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu
Joan Tymon-Rosario, Eric R Siegel, Stefania Bellone, et al.
Gynecologic Oncology
|
January 27, 2023
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo
Chanhee Han, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology
|
January 7, 2023
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
Dennis Mauricio, Stefania Bellone, Levent Mutlu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sangini S Sheth, Ji Eun Oh, Stefania Bellone, et al.
Gynecologic Oncology
|
May 31, 2022
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu
Ghanshyam Yadav, Dana M Roque, Stefania Bellone, et al.
Clinical & Experimental Metastasis
|
June 22, 2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Levent Mutlu, Blair McNamara, Stefania Bellone, et al.
British Journal of Cancer
|
March 4, 2024
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Dana M Roque, Eric R Siegel, Natalia Buza, et al.
Page
of 6